RESUMEN
Introduction. Signal transducer and activator of transcription 3 (STAT3) deficiency is a rare primary immunodeficiency associated with increased susceptibility to bacterial and fungal infections, notably pulmonary aspergillosis.Aim. We describe the emergence of azole-resistant Aspergillus fumigatus infections in STAT3-deficient patients.Methodology. During a retrospective study of 13 pulmonary aspergillosis cases in STAT3-deficient patients conducted in France, we identified patients infected with azole-resistant A. fumigatus isolates.Results. Two out of the 13 STAT3-deficient patients with aspergillosis had azole-resistant A. fumigatus infection, indicating an unexpectedly high prevalence of resistance. The first patient with STAT3 deficiency presented several flares of allergic bronchopulmonary aspergillosis-like episodes. He was chronically infected with two azole-resistant A. fumigatus isolates (TR34/L98). Despite prolonged antifungal treatment, including caspofungin and amphotericin B, the patient was not able to clear the azole-resistant A. fumigatus. The second patient had chronic cavitary pulmonary aspergillosis (CCPA). The A. fumigatus isolate was initially azole susceptible but harboured three F46Y, M172V and E427K point mutations. Despite prolonged antifungal therapies, lesions worsened and the isolate became resistant to all azoles. Surgery and caspofungin treatments were then required to cure CCPA. Resistance was probably acquired from the environment (TR34/L98) in the first case whereas resistance developed under antifungal treatments in the second case. These infections required long-term antifungal treatments and surgery.Conclusions. The emergence of azole-resistant A. fumigatus infections in STAT3-deficiency dramatically impacts both curative and prophylactic antifungal strategies. Physicians following patients with primary immune-deficiencies should be aware of this emerging problem as it complicates management of the patient.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Azoles/uso terapéutico , Farmacorresistencia Fúngica/efectos de los fármacos , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/genética , Factor de Transcripción STAT3/deficiencia , Adulto , Anfotericina B/uso terapéutico , Caspofungina/uso terapéutico , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/genética , Enfermedades Transmisibles/microbiología , Farmacorresistencia Fúngica/genética , Francia , Proteínas Fúngicas/genética , Genotipo , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos , Adulto JovenRESUMEN
Invasive aspergillosis (IA) affects the lungs and disseminates mostly in patients with neutropenia and/or patients who are receiving immunosuppressive and steroid therapies. Despite progress in the diagnosis of and therapy for IA, it is still characterized by a high mortality rate. Currently, voriconazole is considered as the standard therapy for IA. Over recent years, triazole-resistant Aspergillus fumigatus isolates have emerged in the environment due to the use of fungicidal agricultural products, with the risk of developing IA related to a resistant isolate. However, resistance may also develop in patients who are undergoing long-term triazole therapy, particularly in the setting of chronic forms of pulmonary aspergillosis. Herein we describe a kidney transplant recipient who failed to respond to voriconazole therapy due to acquired resistance secondary to the appearance of a de novo mutation (Y121F) in the cyp51A gene during chronic necrotizing pulmonary aspergillosis. The infecting isolate acquired voriconazole resistance in 8 months despite plasma concentrations within the recommended range of the drug, necessitating lobectomy in association with a new antifungal strategy consisting of liposomal amphotericin and caspofungin with a good outcome over 36 months.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Farmacorresistencia Fúngica/efectos de los fármacos , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Trasplante de Riñón/efectos adversos , Voriconazol/farmacología , Anciano , Anfotericina B/uso terapéutico , Caspofungina/uso terapéutico , Sistema Enzimático del Citocromo P-450/genética , Proteínas Fúngicas/genética , Humanos , Aspergilosis Pulmonar Invasiva/etiología , Aspergilosis Pulmonar Invasiva/patología , Masculino , Mutación , PronósticoRESUMEN
Treatment of Candida glabrata cystitis remains a therapeutic challenge, and an antifungal combination using flucytosine is one option. We describe two patients with refractory C. glabrata cystitis who failed flucytosine combined with caspofungin with early-acquired high-level resistance to flucytosine due to nonsense mutations in the FUR1 gene. Rapidly acquired flucytosine resistance with microbiological failure should discourage combination of caspofungin and flucytosine during urinary candidiasis.
Asunto(s)
Antifúngicos/administración & dosificación , Candida glabrata/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Cistitis/tratamiento farmacológico , Farmacorresistencia Fúngica/efectos de los fármacos , Equinocandinas/administración & dosificación , Flucitosina/administración & dosificación , Lipopéptidos/administración & dosificación , Anciano , Secuencia de Bases , Candida glabrata/genética , Candida glabrata/aislamiento & purificación , Candida glabrata/metabolismo , Candidiasis/microbiología , Candidiasis/patología , Caspofungina , Codón sin Sentido , Cistitis/microbiología , Cistitis/patología , Farmacorresistencia Fúngica/genética , Quimioterapia Combinada , Femenino , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Expresión Génica , Humanos , Masculino , Datos de Secuencia Molecular , Proteínas de Transporte de Nucleobases/genética , Proteínas de Transporte de Nucleobases/metabolismo , Insuficiencia del Tratamiento , Vejiga Urinaria/microbiología , Vejiga Urinaria/patologíaRESUMEN
OBJECTIVES: Paradoxical tuberculosis (TB) worsening, an example of the immune reconstitution inflammatory syndrome (IRIS), is an increasing phenomenon now described in several settings, including anti-tumor necrosis factor (TNF) discontinuation during biotherapy-induced TB. To better recognize it, we analyzed the frequency and factors associated with anti-TNF-induced TB-IRIS. METHODS: Case-control study on anti-TNF-associated TB patients. IRIS cases, defined with the following consensus criteria, were matched to two controls (anti-TNF-associated TB without IRIS). IRIS frequency was based on the French RATIO registry. Conditional logistic-regression identified IRIS risk factors. RESULTS: Fourteen patients developed anti-TNF-associated TB-IRIS within medians of 45 [IQR 22-131] days after starting anti-TB therapy and 110 [IQR 63-164] days after the last anti-TNF infusion. Each case was matched to two controls by year of TB diagnosis. IRIS-associated factors were (odds ratio [95% CI]): disseminated TB (11.4 [1.4-92.2], P=0.03), history of Mycobacterium tuberculosis exposure (12.7 [1.6-103.0], P=0.02) and steroid use at the time of TB diagnosis (4.6 [1.2-17.2], P=0.02). The RATIO registry IRIS frequency was 7%. CONCLUSION: After stopping biotherapy, paradoxical anti-TNF-associated TB worsening occurred most often in patients with disseminated TB. Although diagnosis remains difficult, physicians must be aware of IRIS because prolonged anti-TB treatment is not needed but, paradoxically, immunosuppressant reintroduction may be.
Asunto(s)
Artritis/tratamiento farmacológico , Síndrome Inflamatorio de Reconstitución Inmune/inducido químicamente , Inmunosupresores/efectos adversos , Tuberculosis/inducido químicamente , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Anciano , Terapia Biológica/efectos adversos , Estudios de Casos y Controles , Progresión de la Enfermedad , Femenino , Humanos , Síndrome Inflamatorio de Reconstitución Inmune/etiología , Inmunosupresores/uso terapéutico , Tuberculosis Latente/diagnóstico , Masculino , Persona de Mediana Edad , Sistema de Registros , Estudios Retrospectivos , Factores de Riesgo , Enfermedades Cutáneas Vasculares/tratamiento farmacológico , Tuberculosis/etiologíaRESUMEN
Nocardia are Gram-positive filamentous bacteria responsible for infections ranging from opportunistic life-threatening disseminated diseases to chronic skin and soft-tissue infections.Even if virtually all organs can be infected, articular involvement is rare. Therefore, we report 3 recent cases and performed a literature review of cases of Nocardia arthritis in order to describe clinical features, therapeutic challenges, and outcome of these patients.Among 34 patients (31 in the literature plus our 3 cases), 21 (62%) were due to hematogenous dissemination, 9 (26%) were due to direct bacterial inoculation through the skin, and in 4 cases, the mechanism of infection was unknown. Four out of these 34 cases occurred on prosthetic joints.Whereas hematogenous infections mostly occurred in immunocompromised hosts (17 of 21, 81%), direct inoculation was mostly seen in immunocompetent patients.Eighty-two percent of patients (28 out of 34) received trimethoprim-sulfamethoxazole-containing regimens and median antibiotic treatment duration was 24 weeks (range, 12-120) for hematogenous infections and 12 weeks (range, 6-24) for direct inoculations. Outcome was favorable in 27 cases despite unsystematic surgical management (17 cases) without sequelae in 70% of the cases.Nocardia arthritis is rare but its management is complex and should rely on a combined approach with rheumatologist, infectious diseases expert, and surgeon.
Asunto(s)
Artritis/microbiología , Nocardiosis , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Artritis/tratamiento farmacológico , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nocardiosis/tratamiento farmacológico , Adulto JovenAsunto(s)
Enterococcus faecalis/efectos de los fármacos , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Prostatitis/tratamiento farmacológico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , MoxifloxacinoRESUMEN
BACKGROUND: Antibiotics have been shown to improve hidradenitis suppurativa (HS) patients but complete remission is rare using these treatments. OBJECTIVE: To assess the efficacy and safety of a combination of oral rifampin, moxifloxacin and metronidazole in long-lasting refractory HS. METHODS: We retrospectively studied 28 consecutive HS patients including 6, 10 and 12 Hurley stage 1, 2 and 3 patients, respectively. Complete remission, defined as a clearance of all inflammatory lesions including hypertrophic scars, was the main outcome criterion of the study. RESULTS: Complete remission was obtained in 16 patients, including 6/6, 8/10 and 2/12 patients with Hurley stage 1, 2 and 3, respectively (p=0.0004). The median duration of treatment to obtain complete remission was 2.4 (range 0.9-6.5) and 3.8 months (range 1.6-7.4) in stage 1 and 2 patients, respectively, and 6.2 and 12 months in the 2 stage 3 patients. Main adverse events of the treatments were gastrointestinal disorders (64% of patients) and vaginal candidiasis (35% of females). Reversible tendinopathy and hepatitis occurred in 4 and 1 patient, respectively. CONCLUSIONS: Complete remission of refractory HS can be obtained using broad-spectrum antibiotics and Hurley staging is a prognostic factor of response to the treatment.
Asunto(s)
Antiinfecciosos/uso terapéutico , Antibióticos Antituberculosos/uso terapéutico , Compuestos Aza/uso terapéutico , Hidradenitis Supurativa/tratamiento farmacológico , Metronidazol/uso terapéutico , Quinolinas/uso terapéutico , Rifampin/uso terapéutico , Adulto , Antiinfecciosos/efectos adversos , Antibióticos Antituberculosos/efectos adversos , Compuestos Aza/efectos adversos , Quimioterapia Combinada , Femenino , Fluoroquinolonas , Hidradenitis Supurativa/patología , Humanos , Estimación de Kaplan-Meier , Modelos Logísticos , Masculino , Metronidazol/efectos adversos , Persona de Mediana Edad , Moxifloxacino , Pronóstico , Quinolinas/efectos adversos , Recurrencia , Inducción de Remisión , Estudios Retrospectivos , Rifampin/efectos adversos , Resultado del Tratamiento , Adulto JovenRESUMEN
A prospective multicenter surveillance program on yeast bloodstream infections was implemented in the Paris, France, area without restrictions on ward of hospitalization (intensive care unit, hematology, and surgery) or age (adults and children). The present analysis concerns 2,618 isolates collected over 7 years from 2,441 patients. Centralized species identification and antifungal susceptibility testing using the EUCAST methodology were performed. Almost 10% (232/2,441) of the patients had recently (≤30 days) been treated with antifungal drugs. We analyzed the effect of recent exposure to fluconazole (n = 159) or caspofungin (n = 61) on the proportions of the five major Candida species. For both drugs, preexposure was associated with a decreased prevalence of Candida albicans in favor of less drug-susceptible species (C. glabrata and C. krusei for the former and C. parapsilosis and, to a lesser extent, C. glabrata and C. krusei for the latter; P = 0.001). In the multivariate analysis, the risk of being infected with an isolate with decreased susceptibility to fluconazole was independently associated with an age of ≥15 years (odds ratio [OR] = 2.45; 95% confidence interval [CI] = 1.39 to 4.31; P = 0.002) and with recent exposure to fluconazole (OR = 2.17; 95% CI = 1.51 to 3.13; P < 0.001), while the risk of being infected with an isolate with decreased susceptibility to caspofungin was independently associated with an age <15 years (OR = 2.53; 95% CI = 1.43 to 4.48; P = 0.001) and with recent exposure to caspofungin (OR = 4.79; 95% CI = 2.47 to 9.28; P < 0.001). These findings could influence future recommendations for the management of candidemia.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidemia/epidemiología , Equinocandinas/uso terapéutico , Fluconazol/uso terapéutico , Vigilancia de la Población/métodos , Adulto , Antifúngicos/farmacología , Candida/clasificación , Candida/aislamiento & purificación , Candida albicans/efectos de los fármacos , Candidemia/tratamiento farmacológico , Candidemia/microbiología , Caspofungina , Niño , Preescolar , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/epidemiología , Infección Hospitalaria/microbiología , Farmacorresistencia Fúngica , Equinocandinas/farmacología , Fluconazol/farmacología , Francia/epidemiología , Humanos , Lipopéptidos , Pruebas de Sensibilidad Microbiana , Paris/epidemiología , Prevalencia , Estudios Prospectivos , Especificidad de la EspecieRESUMEN
BACKGROUND: Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. METHODS: We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288. FINDINGS: 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89.6%) patients treated with micafungin and 170 (89.5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0.7% (95% CI -5.3 to 6.7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events--including those that were serious or led to treatment discontinuation--with micafungin than there were with liposomal amphotericin B. INTERPRETATION: Micafungin was as effective as--and caused fewer adverse events than--liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis.